Drug Database: Glecaprevir / Pibrentasvir

What is Mavyret?

Mavyret is an antiviral prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the treatment of chronic hepatitis C virus infection (HCV) in adults and children 3 years of age and older who meet certain requirements, as determined by a health care provider.

HCV can be an opportunistic infection (OI) of HIV. An OI is an infection that occurs more frequently or is more severe in people with weakened immune systems—such as people with HIV—than in people with healthy immune systems. To learn more about OIs, read the HIVinfo What is an Opportunistic Infection? fact sheet.

To learn how HIV and HCV are connected, read the HIVinfo HIV and Hepatitis C fact sheet. The fact sheet includes information about how HCV is spread, symptoms of HCV, and treatment options.

How is Mavyret used in people with HIV?

The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV and the AASLD-IDSA HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C include recommendations on the use of Mavyret to treat acute and chronic HCV in people with HIV.

The recommended uses may not always be consistent with FDA-approved uses of Mavyret. See the Adult Opportunistic Infection Guidelines and the AASLD-IDSA HCV Guidelines for complete information on recommended uses of Mavyret in adults and children with HIV. Mavyret may have other recommended uses not listed above.

What should I tell my health care provider before taking Mavyret?

Before taking Mavyret, tell your health care provider:

• If you are allergic to any of the medicines in Mavyret (glecaprevir and pibrentasvir) or any other medicines.
• About any medical conditions you have or have had, especially: 
  • Liver problems, including hepatitis B virus infection (HBV)
  • Liver or kidney transplant
• About anything that could affect your ability to take medicines, such as difficulty swallowing or remembering to take pills.
• If you are pregnant or plan to become pregnant. Talk to your health care provider about the risks and benefits of taking Mavyret during pregnancy. The Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV may include other recommendations on the use of Mavyret during pregnancy. Please refer to these guidelines for additional information.
• If you are breast/chestfeeding or plan to breast/chestfeed. For people with HIV in the United States, the Guideline recommends speaking with your health care provider to discuss options for feeding your baby. People with suppressed viral load have a less than 1% chance of transmitting HIV to their baby via their own milk.
• About other prescription and nonprescription medicines, vitamins, nutritional supplements, and herbal products (including St. John's wort) you are taking or plan to take. Mavyret may affect the way other medicines or products work, and other medicines or products may affect how Mavyret works. Ask your health care provider if there are interactions between Mavyret and the other medicines you take.

Ask your health care provider about possible side effects from Mavyret. Your health care provider will tell you what to do if you have side effects.

How should I take Mavyret?

Take Mavyret according to your health care provider’s instructions. Your health care provider will tell you how much Mavyret to take and when to take it. Before you start Mavyret and each time you get a refill, read any printed information that comes with your medicine.

How should Mavyret be stored?

• Store Mavyret tablets and pellets at or below 86°F (30°C).
• Keep Mavyret in the container that it came in and keep the container tightly closed.
• Do not use Mavyret if the original seal over the container is broken or missing.
• Throw away Mavyret that is no longer needed or expired (out of date). Follow FDA guidelines on how to safely dispose of unused medicine.
• Keep Mavyret and all medicines out of reach of children.

Where can I find more information about Mavyret?

• Recommendations on the HIV-related uses of Mavyret, from the Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV.
• Recommendations on the HIV-related uses of Mavyret, from the HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C.
• This Patient Version drug summary is based on the following FDA label(s): Tablet (film coated), pellet. The Patient Package Insert and Instructions For Use include information for people taking Mavyret.
• The American Hospital Formulary Service (AHFS) Patient Medication Information for glecaprevir and pibrentasvir available from MedlinePlus.
• Mavyret-related research studies, from ClinicalTrials.gov. (The ClinicalTrials.gov search can be modified so that you can get results that better match your interests.)